<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00411047</url>
  </required_header>
  <id_info>
    <org_study_id>04-291</org_study_id>
    <secondary_id>IRUSIRES0483</secondary_id>
    <nct_id>NCT00411047</nct_id>
  </id_info>
  <brief_title>Gefitinib in Treating Patients With Previously Untreated Stage IIIB or Stage IV Non-Small Cell Lung Cancer</brief_title>
  <official_title>A Phase II, Open Label Study of Gefitinib (IRESSA) in Treatment-Naïve Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer and Somatic Activating Mutations in the Epidermal Growth Factor Receptor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Gefitinib may stop the growth of tumor cells by blocking some of the enzymes&#xD;
      needed for cell growth.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well gefitinib works in treating patients with&#xD;
      previously untreated stage IIIB or stage IV non-small cell lung cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the objective tumor response rate in patients with previously untreated stage&#xD;
           IIIB or IV non-small cell lung cancer with somatic activating mutations in the TK region&#xD;
           of the epidermal growth factor receptor (EGFR) gene treated with gefitinib.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine response duration, progression-free survival, and overall survival of patients&#xD;
           treated with this drug.&#xD;
&#xD;
        -  Determine the safety of this drug in these patients.&#xD;
&#xD;
        -  Compare the ability of various somatic activating mutations in the TK region of the EGFR&#xD;
           gene to predict response in patients treated with this drug.&#xD;
&#xD;
        -  Compare the ability of various somatic activating mutations in the TK region of the EGFR&#xD;
           gene to predict toxicity of this drug in these patients.&#xD;
&#xD;
        -  Define a molecular profile in patients who initially respond to treatment with this drug&#xD;
           but subsequently progress on therapy.&#xD;
&#xD;
        -  Determine the significance of germline polymorphisms of the EGFR gene, somatic&#xD;
           amplification of the EGFR gene, and other molecular factors for their association with&#xD;
           clinical outcome parameters in these patients.&#xD;
&#xD;
      OUTLINE: This is an open-label study.&#xD;
&#xD;
      Patients receive oral gefitinib once daily on days 1-28. Courses repeat every 28 days in the&#xD;
      absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed every 2 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">January 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective tumor response rate</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response duration, progression-free survival, and overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ability of various somatic activating mutations in the TK region of the epidermal growth factor receptor (EGFR) gene to predict response and toxicity</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Molecular profile</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Significance of germline polymorphisms of the EGFR gene, somatic amplification of the EGFR gene, and other molecular factors for their association with clinical outcome parameters</measure>
  </secondary_outcome>
  <enrollment type="Actual">34</enrollment>
  <condition>Lung Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gefitinib</intervention_name>
    <description>oral drug taken daily around the same time</description>
    <other_name>IRESSA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Pathologically confirmed non-small cell lung cancer (NSCLC)&#xD;
&#xD;
               -  No squamous cell histology&#xD;
&#xD;
          -  Stage IIIB (with pleural effusion) or stage IV disease&#xD;
&#xD;
          -  Must meet ≥ 1 of the following criteria:&#xD;
&#xD;
               -  Female&#xD;
&#xD;
               -  Adenocarcinoma tumor histology&#xD;
&#xD;
               -  No history of smoking, defined as smoking &lt; 100 cigarettes (5 standard packs of&#xD;
                  cigarettes) in a lifetime, &lt; 20 oz of pipe tobacco in a lifetime, OR &lt; 100 cigars&#xD;
                  in a lifetime&#xD;
&#xD;
               -  Asian/Pacific Rim ethnicity, defined as Japanese, Chinese, Korean, or other&#xD;
                  Asian/Pacific Rim ethnicity&#xD;
&#xD;
          -  Must have activating mutations in the TK region of the epidermal growth factor&#xD;
             receptor (EGFR) gene&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
          -  No symptomatic or newly diagnosed CNS metastases that have not been definitively&#xD;
             treated with radiotherapy and/or surgery&#xD;
&#xD;
               -  History of CNS metastases or cord compression allowed if definitively treated and&#xD;
                  clinically stable&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Life expectancy ≥ 12 weeks&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 2,000/mm³&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm³&#xD;
&#xD;
          -  Bilirubin ≤ 1.25 times upper limit of normal (ULN)&#xD;
&#xD;
          -  ALT and AST ≤ 2.5 times ULN (5 times ULN if liver has tumor involvement)&#xD;
&#xD;
          -  Creatinine ≤ 1.5 times ULN OR creatinine clearance ≥ 60 mL/min&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No known severe hypersensitivity to gefitinib or any other component of gefitinib&#xD;
             tablets&#xD;
&#xD;
          -  No evidence of clinically active interstitial lung disease&#xD;
&#xD;
               -  Patients with chronic, stable radiographic changes who are asymptomatic are&#xD;
                  eligible&#xD;
&#xD;
          -  No other concurrent malignancy or malignancy diagnosed within the past 5 years except&#xD;
             for basal cell carcinoma of the skin or cervical cancer in situ&#xD;
&#xD;
          -  No concurrent severe or uncontrolled systemic disorder&#xD;
&#xD;
          -  No evidence of any other significant clinical disorder or laboratory finding that, in&#xD;
             the opinion of the investigator, would preclude study participation&#xD;
&#xD;
          -  Able to tolerate protocol treatment, in the opinion of the investigator&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior systemic chemotherapy, biological therapy, immunotherapy, or hormonal therapy&#xD;
             for NSCLC, including adjuvant and neoadjuvant treatment&#xD;
&#xD;
          -  No prior radiotherapy to the target lesion&#xD;
&#xD;
               -  Prior radiotherapy to bony disease or CNS disease allowed&#xD;
&#xD;
          -  At least 2 weeks since prior radiotherapy and recovered&#xD;
&#xD;
          -  More than 30 days since prior non-FDA approved or investigational agents&#xD;
&#xD;
          -  No prior EGFR antagonists&#xD;
&#xD;
          -  At least 2 weeks since prior and no concurrent phenytoin, carbamazepine, rifampin,&#xD;
             barbiturates, or Hypericum perforatum (St. John's wort)&#xD;
&#xD;
          -  No concurrent chemotherapy, immunotherapy, hormonal therapy, nonpalliative&#xD;
             radiotherapy, surgery for cancer, or other experimental medications&#xD;
&#xD;
          -  No other concurrent specific antitumor therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lecia V Sequist, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://cancer.gov/clinicaltrials</url>
    <description>Clinical trial summary from the National Cancer Institute's PDQ® database</description>
  </link>
  <verification_date>May 2013</verification_date>
  <study_first_submitted>December 11, 2006</study_first_submitted>
  <study_first_submitted_qc>December 11, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 13, 2006</study_first_posted>
  <last_update_submitted>May 12, 2013</last_update_submitted>
  <last_update_submitted_qc>May 12, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 14, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Lecia V. Sequist</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>stage IIIB non-small cell lung cancer</keyword>
  <keyword>stage IV non-small cell lung cancer</keyword>
  <keyword>adenocarcinoma of the lung</keyword>
  <keyword>bronchoalveolar cell lung cancer</keyword>
  <keyword>large cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gefitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

